- Preclinical data demonstrates complete functionality of SENTI-202 OR+NOT Logic Gated gene circuits for the elimination of AML cancer cells…
Keros Therapeutics will be hosting a conference call and webcast today, December 13, 2021, at 4:01 p.m. ET.LEXINGTON, Mass., Dec.…
6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of…
B-AMAZE long-term follow up data demonstrate sustained FIX expression up to 3.5 years; potential for expression levels in the normal…
Data Presented in Poster Presentation at American Society of Hematology Annual MeetingBURLINGAME, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Corvus…
BRISBANE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class…
95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd…
-- Two dose levels studied (100 and 300 million CAR+ T-cells); MTD not reached -- -- 100% ORR at both…
GBT601 demonstrated average hemoglobin occupancy of greater than 30% with 100 mg daily doses in a multiple ascending dose study…
ROCKAWAY, NJ, Dec. 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today…